BPA Open Scientific - Dr David Erritzoe, Psychedelics in Psychiatry

BPA Open Scientific - Dr David Erritzoe, Psychedelics in Psychiatry

Actions and Detail Panel

Sales Ended

Date and time

Location

Online event

Dr David Erritzoe, MD, PhD, MRCPsych Imperial College London Psychedelics in Psychiatry - State of Play

About this event

Psychedelics in Psychiatry - State of Play

In clinical and research settings around the world, after a period of being banned, psychedelic substances are being used to assist in the treatment of ailments such as addiction, depression, anxiety and trauma. Working with micro-doses that affect neural circuits together with talking therapies, Dr Erritzoe will update us on the research and clinical findings.

Dr David Erritzoe is Clinical Senior Lecturer and Consultant Psychiatrist at Imperial College London and in CNWL Mental Health NHS Foundation Trust. David conducts psychopharmacological research, using brain-imaging techniques such as PET and MRI and has a PhD in this area. Since 2009 he has been involved in post-doc imaging research in the neurobiology of addictions and major depression at Imperial. As clinical director and deputy head in the Centre for Psychedelic Research, he investigates mechanisms and therapeutic potential of MDMA, ketamine and classic psychedelics [trials in depression, OCD, anorexia nervosa], and in early 2021 David set up a new NHS-based psychopharmacology & psychedelic research Clinic at St Charles Hospital in London, named the CIPPRes Clinic.

The opinions and views expressed are entirely those of the speaker in a personal capacity and do not necessarily reflect the policies or opinions of the BPA.

A Zoom link will be sent closer to the date.